Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction.
BACKGROUND
Lung volume reduction surgery is effective at improving lung function, quality of life, and mortality in carefully selected individuals with advanced emphysema. Recently, less invasive bronchoscopic approaches have been designed to utilize these principles while avoiding the associated perioperative risks. The Endobronchial Valve for Emphysema PalliatioN Trial (VENT) posits that occlusion of a single pulmonary lobe through bronchoscopically placed Zephyr endobronchial valves will effect significant improvements in lung function and exercise tolerance with an acceptable risk profile in advanced emphysema.


METHODS
The trial design posted on Clinical trials.gov, on August 10, 2005 proposed an enrollment of 270 subjects. Inclusion criteria included: diagnosis of emphysema with forced expiratory volume in one second (FEV1) < 45% of predicted, hyperinflation (total lung capacity measured by body plethysmography > 100%; residual volume > 150% predicted), and heterogeneous emphysema defined using a quantitative chest computed tomography algorithm. Following standardized pulmonary rehabilitation, patients were randomized 2:1 to receive unilateral lobar placement of endobronchial valves plus optimal medical management or optimal medical management alone. The co-primary endpoint was the mean percent change in FEV1 and six minute walk distance at 180 days. Secondary end-points included mean percent change in St. George's Respiratory Questionnaire score and the mean absolute changes in the maximal work load measured by cycle ergometry, dyspnea (mMRC) score, and total oxygen use per day. Per patient response rates in clinically significant improvement/maintenance of FEV1 and six minute walk distance and technical success rates of valve placement were recorded. Apriori response predictors based on quantitative CT and lung physiology were defined.


CONCLUSIONS
If endobronchial valves improve FEV1 and health status with an acceptable safety profile in advanced emphysema, they would offer a novel intervention for this progressive and debilitating disease.


BACKGROUND
ClinicalTrials.gov: NCT00129584.
Strange
Charlie
C
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA. strangec@musc.edu
Herth
Felix J F
FJ
Kovitz
Kevin L
KL
McLennan
Geoffrey
G
Ernst
Armin
A
Goldin
Jonathan
J
Noppen
Marc
M
Criner
Gerard J
GJ
Sciurba
Frank C
FC
D001999:Bronchoscopy; D004646:Emphysema / Q000628:therapy*; D006801:Humans; D010166:Palliative Care / Q000379:methods*; D011013:Pneumonectomy / Q000295:instrumentation*; D019736:Prostheses and Implants; D011474:Prosthesis Design
Chest. 1999 Dec;116(6):1608-15
10593784
Eur Respir J. 2006 Sep;28(3):523-32
16611654
Clin Ther. 2000 Sep;22(9):1121-45
11048909
Lancet. 2003 Mar 15;361(9361):931-3
12648974
N Engl J Med. 2003 May 22;348(21):2059-73
12759479
Clin Radiol. 1982 Jul;33(4):379-87
7083738
J Chronic Dis. 1984;37(2):85-95
6420431
Am Rev Respir Dis. 1986 Apr;133(4):541-6
3963623
Am J Respir Crit Care Med. 1994 Sep;150(3):635-41
8087331
N Engl J Med. 1996 Apr 25;334(17):1095-9
8598868
Chest. 1996 May;109(5):1163-8
8625661
Am J Respir Crit Care Med. 1997 Apr;155(4):1278-82
9105067
Am J Respir Crit Care Med. 1997 Jun;155(6):1984-90
9196106
J Cardiovasc Surg (Torino). 1998 Apr;39(2):237-43
9639013
Radiology. 1999 Jun;211(3):851-8
10352615
Ann Thorac Surg. 2005 Feb;79(2):411-6; discussion 416-7
15680805
Am J Respir Crit Care Med. 2005 Mar 1;171(5):453-60
15579725
Rev Mal Respir. 2004 Dec;21(6 Pt 1):1144-52
15767960
Eur Respir J. 2005 Nov;26(5):948-68
16264058
Chest. 2005 Dec;128(6):3799-809
16354848
Chest. 2006 Mar;129(3):518-26
16537847
Chest. 2006 Jul;130(1):190-9
16840401
N Engl J Med. 2000 Jul 27;343(4):239-45
10911005